https://scholars.lib.ntu.edu.tw/handle/123456789/512188
標題: | Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists | 作者: | Wang C.-Y. Lin Y.S. Wang Y.-H. Lai C.-C. HAO-CHIEN WANG Chen L. CHONG-JEN YU Perng D.-W. Cheng S.-L. Hsu J.-Y. Hsu W.-H. Tsai Y.-H. Hsiue T.-R. Lin M.-C. Lin H.-I. Wang C.-Y. YEUN-CHUNG CHANG Yang U.-C. Chen C.-M. Lin C.-S. Chen L. Wei Y.-F. Chong I.-W. CHUNG-YU CHEN On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE) |
公開日期: | 2019 | 出版社: | Impact Journals LLC | 卷: | 11 | 期: | 17 | 起(迄)頁: | 6863-6871 | 來源出版物: | Aging | 摘要: | This study aimed to compare the effect of budesonide/formoterol and fluticasone/salmeterol on the risk and outcomes of sepsis in COPD patients. We conducted this study using the Taiwan National Health Insurance Research Database. We included COPD patients prescribed with budesonide/formoterol or fluticasone/salmeterol between 2004 and 2011. Outcomes including sepsis and mortality were measured. 10,267 COPD patients who received fluticasone/salmeterol and 6,844 patients who received budesonide/formoterol were enrolled into this study and then subsequence were adjusted by propensity score weighting. The incidence of sepsis was 5.74 and 4.99 per 100 person-years for the patients receiving fluticasone/salmeterol and budesonide/formoterol, respectively. Fluticasone/salmeterol was associated with higher risk of sepsis (aHR, 1.15; 95%CI, 1.07-1.24) and septic shock (aHR, 1.14; 95%CI, 1.01-1.29) than budesonide/formoterol. Besides, fluticasone/salmeterol was associated with higher risk of death (aHR, 1.090; 95%CI, 1.01-1.18) than budesonide/formoterol. Patients receiving fluticasone/salmeterol had a significant higher risk of sepsis related respiratory organ dysfunction, lower respiratory tract infection, genitourinary tract infection, bacteremia and skin infection. In conclusion, long-term treatment with budesonide/formoterol was associated with lower rates of sepsis and deaths than fluticasone/salmeterol in patients with COPD. ? Wang et al. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072307003&doi=10.18632%2faging.102217&partnerID=40&md5=2e01c761ae4ca92d8c2382a9db4b8c52 https://scholars.lib.ntu.edu.tw/handle/123456789/512188 |
ISSN: | 1945-4589 | DOI: | 10.18632/aging.102217 | SDG/關鍵字: | beta 2 adrenergic receptor stimulating agent; bronchodilating agent; budesonide plus formoterol; corticosteroid; fluticasone propionate plus salmeterol; chronic obstructive lung disease; female; human; incidence; male; middle aged; sepsis; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Budesonide, Formoterol Fumarate Drug Combination; Female; Fluticasone-Salmeterol Drug Combination; Humans; Incidence; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Sepsis |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。